Sanofi has agreed to buy cancer biotech company Synthorx for $2.5 billion, the first big move by new Chief Executive Paul Hudson to reinvigorate the sprawling French health-care giant.
The company has a long history in cancer-drug development but has fallen behind in the latest rush to develop immunotherapies, or drugs that help the immune system fight tumors. Its acquisition of Synthorx is a bet that it can make up that ground.
Synthorx, based in La Jolla, Calif., is developing a drug that aims to boost the immune system’s response to cancer. The drug is in the early phase of human testing in a range of cancers, both on its own and in combination with existing cancer immunotherapies. Sanofi on Monday said it would pay $68 a share in cash for Synthorx, a 172% premium to the smaller company’s closing share price Friday.
“This acquisition fits perfectly with our strategy to build a portfolio of high-quality assets and to lead with innovation,” said Mr. Hudson, who is set to provide an eagerly awaited strategy update to investors Tuesday.
Full Content: Wall Street Journal
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
FTC Sues to Block Tempur Sealy’s $4.3 Billion Acquisition of Mattress Firm
Oct 24, 2024 by
CPI
Mexican Watchdog Proposes Fintech Reforms to Boost Financial Inclusion
Oct 24, 2024 by
CPI
AMA and ISMS File Antitrust Lawsuit Against MultiPlan Over Alleged Price-Fixing Scheme
Oct 24, 2024 by
CPI
Biden Administration Announces New AI Strategy to Boost National Security
Oct 24, 2024 by
CPI
Google Agrees to Provide AI-Related Documents in Monopoly Case
Oct 24, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Chevron
Oct 24, 2024 by
CPI
A Quartet of Decisions That Cripple Agencies
Oct 24, 2024 by
Richard J. Pierce
Goodbye, Chevron: Rediscovering the Virtues of an Independent Judiciary
Oct 24, 2024 by
Alexander Volokh
A New Era of Deference: From Chevron to Loper Bright
Oct 24, 2024 by
Daniel E. Walters
Loper Bright and Antitrust: Limited Impact on Enforcement, but a Clear Constraint on FTC Rulemaking
Oct 24, 2024 by
David Kully, Lynn Calkins & Kenneth Racowski